Genor biopharma's lerociclib added to China's national drug list

Genor Biopharma Holdings Limited announced on December 8, 2025, that its drug Lerociclib (GB491) has been included in the 2025 edition of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance. This marks the first time Lerociclib (GB491) has achieved such inclusion, with the new list set to take effect from January 1, 2026.

Lerociclib (GB491) is a novel, highly potent, selective, oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i). It is indicated for treating adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, or fulvestrant for patients with disease progression post-endocrine therapy.

The company anticipates that this inclusion will enhance patient access, reduce financial burdens, and accelerate the commercialization and market penetration of Lerociclib (GB491), thereby increasing returns on innovation.